-
1.发明申请
公开(公告)号：WO2020132493A1
公开(公告)日：2020-06-25
申请号：PCT/US2019/067936
申请日：2019-12-20
Applicant: CLAUSS, Matthias Alexander , MAIER, Bernhard F. , CHELVANAMBI, Sarvesh , INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Inventor： CLAUSS, Matthias Alexander , MAIER, Bernhard F. , CHELVANAMBI, Sarvesh
Abstract: Therapeutic compositions comprising one or more agents that inhibit the Nef-PAK2 interface, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent, and diagnose a condition/disease associated with HIV-infection or a related clinical condition thereof, are disclosed.
-
公开(公告)号：WO2019241311A1
公开(公告)日：2019-12-19
申请号：PCT/US2019/036639
申请日：2019-06-11
Inventor： THAKUR, Ganeshsingh, A. , LOGOTHETIS, Diomedes, E. , CANTWELL, Lucas , XU, Yu , SHEKAR, Anantha
IPC: A61K31/415 , C07D231/40 , A61P25/00
Abstract: Selective small molecule regulators of GIRK potassium channels are provided, which are effective in treatment of post-traumatic stress disorder and other medical conditions.
-
3.发明申请
公开(公告)号：WO2019241105A1
公开(公告)日：2019-12-19
申请号：PCT/US2019/036278
申请日：2019-06-10
Inventor： JIN, Jian-Yue , PI, Wenhu , KONG, Feng-Ming , WANG, Weili
Abstract: Methods for directly measuring a patient's relative sensitivity to radiation therapy are provided. In particular, the methods provide for calculating a radiation sensitivity quotient for monocytes in culture. The methods can be incorporated into radiotherapy (RT) treatment planning systems, which are also provided. The methods can be used to optimize patient treatment plans, thereby developing patient-specific radiation treatment plans. Methods for treating a patient with radiotherapy with an optimized treatment plan are provided.
-
公开(公告)号：WO2019016819A1
公开(公告)日：2019-01-24
申请号：PCT/IL2018/050807
申请日：2018-07-20
Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. , INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
Inventor： DOMB, Abraham Jacob , KUBEK, Michael
IPC: A61K9/00 , A61K38/06 , A61K38/09 , A61K38/11 , A61K9/14 , A61K9/51 , A61K38/13 , A61K31/352 , A61K31/573 , A61K31/616
Abstract: Compositions comprising nanoparticles are described herein. At least a portion of the nanoparticles comprises a lipid and/or polymer which is water-insoluble, and an agent incorporated in the lipid and/or polymer. The nanoparticles are optionally associated with a surface of water-soluble particles which comprise a water-soluble compound. The polymer is optionally a polyanhydride. Further described herein are processes for preparing such compositions, comprising contacting a solution comprising the lipid and/or polymer dissolved in a non-aqueous solvent with an anti-solvent (in which the lipid and/or polymer and agent are insoluble) which is miscible with the non-aqueous solvent. Further described herein are uses of the compositions for nasal administration, and devices configured for nasal administration of the composition upon atomization.
-
公开(公告)号：WO2019006074A1
公开(公告)日：2019-01-03
申请号：PCT/US2018/039923
申请日：2018-06-28
Inventor： ZARRINMAYEH, Hamideh , GREEN, Mark, Alan
IPC: A61K31/40 , A61K31/4015 , A61K31/402 , C07D207/04 , C07D207/18 , C07D207/24
Abstract: Disclosed are P2X7 receptor ligands having the formula (I) in which R = -(CH 2 ) n -(O-CH 2 CH 2 ) m -O l -(CH 2 ) p -X, l= 0-1, m = 0-6, n = 2-3, p = 0-2, and X = Br, CI, F or 18 F. In illustrative embodiments, R = -(CH 2 ) n , and n = 2-3. The receptor ligands are used in methods related to conditions related to the P2X7 receptor. The non-radioligands are useful for modulating inflammation conditions associated with the P2X7 receptor. The radioligands, containing 18 F, are useful for as radiotracers in imaging processes, and thus for the detection and evaluation of inflammation and therapies. Also provided are processes for preparation of these P2X7 receptor ligands.
-
Patent Agency Ranking
公开(公告)号：WO2018236733A1
公开(公告)日：2018-12-27
申请号：PCT/US2018/038039
申请日：2018-06-18
CPC classification number: G06F11/3644 , G06F11/302 , G06F11/3093
Abstract: A method provides for injecting a probe (302) into a computer-readable computer program having a plurality of computer-executable instructions (134). In one example, the method includes receiving the plurality of computer-executable instructions (134) from memory (130); identifying at least one original instruction (308) from the received plurality of computer-executable instructions (134) for facilitating insertion of the probe (302); creating a temporary copy of the at least one original instruction (308); and allocating a jump target of the probe (302) to a memory address in the memory (130) by assigning a predetermined value to tail bytes (312) of the probe (302).
-
公开(公告)号：WO2018175429A1
公开(公告)日：2018-09-27
申请号：PCT/US2018/023346
申请日：2018-03-20
Inventor： KELLEY, Mark R. , FISHEL, Melissa L.
IPC: C07K16/28 , C07K16/30 , A61K31/195 , A61K31/4741 , A61K31/282
Abstract: Combination therapies including a Apurinic/Apyrimidinic Endonuclease/reduction-oxidation (redox) Factor-1 (APE1/Ref-1) inhibitor specific to inhibit the redox function of APE1/Ref-1 are disclosed herein. The Combination therapies can be used for treating various cancers, as well as other angiogenesis-mediated diseases (e.g., retinal diseases, cardiovascular diseases).
-
公开(公告)号：WO2018089875A3
公开(公告)日：2018-05-17
申请号：PCT/US2017/061254
申请日：2017-11-13
Applicant: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION , SCHLEYER, Titus, Karl, Ludwig , MILED, Zina, Ben , KING, Zachary, Doyle
IPC: G06Q50/00
Abstract: Methods for providing a health record architecture, comprising linking a patient's health information to relevant health data, automatically determining an applicability of current medical evidence, recommendations, or combinations thereof to the patient, and enriching a health record from external data sources are disclosed. Health record architectures are also disclosed.
-
公开(公告)号：WO2018064581A1
公开(公告)日：2018-04-05
申请号：PCT/US2017/054508
申请日：2017-09-29
Inventor： PEPPLER, Kylie Aine , DANISH, Joshua
CPC classification number: H04W4/029 , G01S5/00 , G01S5/14 , G01S13/72 , G01S13/765 , G01S13/825 , G01S13/878 , G06F3/14 , H04W24/08
Abstract: An indoor positioning system comprising at least three anchors, at least one actor configured to interact with the at least three anchors, and an electronic device in communication with at least one of the at least three anchors, the electronic device being configured to receive two-way ranging/distance data for each actor and calculate a real-time position of each actor within a room based on the two-way ranging/distance data, the two-way ranging/distance data including a round-trip time of a radio frequency signal between the at least one actor and each of the at least three anchors.
Abstract translation: 一种室内定位系统，包括至少三个锚定器，至少一个配置成与所述至少三个锚定器相互作用的参与者以及与所述至少三个锚定器中的至少一个锚定器通信的电子设备，所述 电子设备被配置为接收每个演员的双向测距/距离数据，并基于双向测距/距离数据计算房间内每个演员的实时位置，双向测距/距离数据包括 在至少一个参与者与至少三个锚点中的每一个锚点之间的射频信号的往返时间
-
公开(公告)号：WO2017210241A1
公开(公告)日：2017-12-07
申请号：PCT/US2017/035101
申请日：2017-05-31
Inventor： DIMARCHI, Richard D. , MAYER, John P. , MROZ, Piotr
IPC: A61K38/00 , A61K38/16 , A61K38/26 , C07K14/605
Abstract: Modified glucagon peptides are disclosed having improved solubility and/or stability while retaining glucagon agonist activity. The glucagon peptides have been modified by the substitution of pyridyl-alanine for a native amino acid at one or more of positions 6, 10 or 13 and/or substitution with an amino acid in the D-conformation at position 20 or 21 compared to native glucagon.
Abstract translation: 公开了在保持胰高血糖素激动剂活性的同时具有改善的溶解度和/或稳定性的修饰的胰高血糖素肽。 胰高血糖素肽已经通过吡啶基丙氨酸取代6位，10位或13位的一个或多个天然氨基酸和/或用20位或21位的D构型中的氨基酸取代为天然氨基酸 胰高血糖素。
-
-
-
-
-
-
-
-
-
Search Results
382
records
(took 0.014 seconds)
